Physician profile
Jamal Ross
NPI 1205156429
$635.31
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $63.38 · 2021: $62.77 · 2022: $223.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $220.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $92.35 | 2019-2020 | |
| Pfizer INC. | $55.87 | 2019-2021 | |
| Allergan, INC. | $53.97 | 2019 | |
| Vyera Pharmaceuticals, LLC | $43.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.74 | 2019 | |
| Mylan Specialty L.P. | $24.78 | 2019 | |
| Lilly USA, LLC | $22.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.24 | 2022 | |
| Nabriva Therapeutics, Plc | $16.27 | 2020 | |
| Vifor Pharma, INC. | $14.54 | 2019 | |
| Phadia US INC. | $13.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.